Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 7Sarcoma 5Melanoma 5Lymphoma, Non-Hodgkin 5Prostatic Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Endometrial Neoplasms 4Carcinoma, Hepatocellular 4Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Kidney Neoplasms 3Glioblastoma 3Squamous Cell Carcinoma of Head and Neck 2Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Lymphoma, Mantle-Cell 2Liver Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Congenital Abnormalities 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1

Interventions

Octreotide 4Everolimus 4Capecitabine 3Temozolomide 2Melphalan 2Biological Therapy 2vatalanib 1temsirolimus 1romidepsin 1regorafenib 1motesanib diphosphate 1folfirinox 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1Thalidomide 1Streptozocin 1Sorafenib 1Sirolimus 1Leucovorin 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Gefitinib 1Fluorouracil 1Filgrastim 1Cytokines 1Complementary Therapies 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Islet Cell × temsirolimus × Clear all
NCT00093782 2017-02-07

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
36 enrolled 12 charts

Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡